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Surgical Management of Children
With Locally Advanced
Hepatoblastoma
We read with great interest the article by Lautz et al ti-
tled ‘‘Successful nontransplant resection of POST-TEXT
III and IV hepatoblastoma.’’1 The authors document
excellent results with a difficult subgroup of children with
hepatoblastoma. We agree with their conclusion that
referral to a center specializing in pediatric hepatobiliary
surgery should not be considered a referral for a predes-
tined liver transplant, even if the child has a hepatoblas-
toma that is extensive and potentially unresectable.
Rather, it is a referral to a center where the expertise is
available to perform a complex liver resection or a trans-
plant, in children, where it is often not possible to know
which is the better treatment in a disease where complete
surgical resection is essential for cure.
This article points out the challenges of providing
definitive surgical care for such children. One child died
and 2 of the 13 survivors had major vascular complica-
tions: 1 required urgent salvage liver transplant for ische-
mic cholangiopathy and 1 required a splenorenal shunt
for postoperative thrombosis of the portal vein. Even in
experienced hands, such major vascular complications
will occur. This risk, plus the extensive literature showing
improved oncology outcomes with upfront, rather than
‘‘rescue,’’ liver transplant, has driven the increased and
highly successful use of liver transplantation in this disease
over the past decade.
We question the authors’ conclusion that PRE-
TEXT should not be used as a triage tool because it has a
tendency to overstage. The PRETEXT system has been
used effectively in European SIOPEL [Liver tumor study
group of the International Society of Pediatric Oncology
(SICP)] multicenter studies to triage those children with
aggressive tumors to the centers best able to manage the
operative challenges the authors note. SIOPEL multi-
center studies 1, 2, and 3 have documented improved
patient survival with this approach. In fact, one of the
major study objectives of AHEP-0731 is to determine the
accuracy of the PRETEXT/POST-TEXT group in pre-
dicting surgical resection.
Finally, and perhaps most importantly, we would
call attention to a small but very important misstatement
in the article’s quotation of the surgical guidelines in the
current Children’s Oncology Group (COG) protocol
AHEP-0731 ‘‘Treatment of Children with all Stages of
Hepatoblastoma.’’ In the last sentence on page 1976, the
authors state, ‘‘Children with POST-TEXT III and IV
tumors are referred to a surgical center with expertise in
pediatric liver transplant and extreme liver resection at di-
agnosis if possible and no later than just after the second
cycle of chemotherapy.’’ First, the correct terminology for
the chemotherapy classification at diagnosis is PRETEXT;
classification after neoadjuvant chemotherapy is POST-
TEXT. Second and more importantly is to emphasize that
COG AHEP-0731 does not recommend referral of all
patients with PRETEXT/POST-TEXT III tumors, only
the subset of children with POST-TEXT III tumors who
demonstrate persistent major vascular involvement after
neoadjuvant chemotherapy. POST-TEXT III tumors
without major vascular involvement are considered ‘‘re-
sectable’’ by the COG AHEP-0731 protocol and do not
need to be referred to a specialty liver center. AHEP-0731
does recommend referral for all patients with POST-
TEXT IV tumors. Because of inferior outcomes seen in
previous large multicenter studies, the protocol does not
recommend piecemeal nonanatomic resection of these
POST-TEXT IV tumors when they aremultifocal.
Under ideal circumstances, we would suggest that
all children in the United States with hepatoblastoma
should be enrolled in AHEP-0731 and wish to assure
readers that the COG surgical guidelines are just that:
they are guidelines. Our committee would welcome the
opportunity to clarify any questions surgeons or oncolo-
gists might have regarding this study, which was designed
with the goal espoused in the article’s conclusion ‘‘. . .to
provide the best oncologic therapy for each individual
child while limiting unnecessary long-termmorbidity.’’
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Comments on Surgical Treatment
of Locally Advanced
Hepatoblastoma
We would like to comment on the very interesting,
albeit controversial, article by Lautz et al titled ‘‘Successful
nontransplant resection of POST-TEXT III and IV
hepatoblastoma.’’1 The authors state that 93% (13 of
14 patients) of POST-TEXT III and IV hepatoblasto-
mas referred to their institution were successfully
resected by conventional means, despite the patients
being potential candidates for liver transplantation.
However, the diagnostic staging of some of these
tumors raises concerns because the original PRETEXT
was unknown and based on local assessment only in 6
patients referred from other institutions, whereas we
know from the SIOPEL 4 trial analysis that 20% of
patients classified as PRETEXT IV locally were reclas-
sified on central review (unpublished data). In addi-
tion, in our opinion, figure 1A in Lautz et al, which is
presented as POST-TEXT IV, appears to be POST-
TEXT III on the images shown and hence resectable
by conventional left trisegmentectomy. Moreover, 3 of
the 8 remaining cases were PRETEXT III (only 1 of
them was associated with complete portal involvement:
P2), which suggests that at least two of them were
potentially resectable from the beginning of treatment.
Therefore, comparison of this study with other series
and trials is difficult.
The authors report 93% survival after nontrans-
plant resection in patients who might have otherwise
been considered for primary transplantation, but their
follow-up is less than 2 years in 4 patients, and the 5-
year overall survival seems to be 88% with a 5-year
event-free survival of 75%. In addition, survival in the
last case is uncertain taking into account the long inter-
val from the resection to the first relapse (48 months)
and insufficient follow-up after the second resection
(30 months). Thus, in our opinion, the 5-year event-
free survival of 75%, as stated in the report, is a more
useful measure. This is similar to the SIOPEL
experience.2,3
We are concerned that the message from this article
might be misleading and might encourage inappropriate
surgical strategy in less experienced hands. In particular,
‘‘shaving a margin or performing a separate wedge resec-
tion from the remaining sector of liver’’ and ‘‘using an
ultrasonic device to clear residual hepatocytes from the
vessel when the abutting tumor is truly adherent’’ are not
standard practices and should not be recommended when
liver transplantation is available.4,5
Ten patients had a POST-TEXT III, centrally
located tumor with encasement, invasion, or close prox-
imity of the main hilar structures or all 3 hepatic veins af-
ter neoadjuvant chemotherapy. The details of vascular
involvement reported in table 1 of Lautz et al (P0V2, P1,
P1, P0V1, P1, P0, P1V1, P1V1, P0V1) suggest that the
majority of these patients would not require transplanta-
tion under current surgical guidelines. The exception is
the 2 PRETEXT IV multifocal cases downstaged to
POST-TEXT III by neoadjuvant chemotherapy. The pol-
icy of the SIOPEL group remains that these patients
should be treated by transplantation, until there is evi-
dence that this is unnecessary.4 Ideally, a randomized,
controlled trial would be performed, but this is unlikely to
be practical.
The authors state that ‘‘Although inconclusive,
existing evidence does not link microscopic residual
disease with tumor recurrence or death.’’ Indeed, in
most patients in the SIOPEL studies, a microscopic
positive margin was not associated with worse out-
come.2 Various explanations may be proposed for this
finding. It is possible that microscopic residual disease
in a chemosensitive tumor will reliably succumb to
adjuvant chemotherapy. Alternatively, it may be that
microscopic residual disease is a risk factor for recur-
rence, but that existing studies have failed to detect
this effect. The actual surgical margin may be difficult
to interpret, because cautery artifact may result in a
thick eschar of burned tissue. Microscopic residual tu-
mor found in the operative specimen may have no
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counterpart on the preserved liver. Also, the ultrasonic
dissector aspirates approximately 5 mm of liver tissue
at the margin of resection, and so may have removed
all of the residual tumor.
Despite this, the general rule should remain a com-
plete, surgical resection with a margin of at least 1 cm of
normal parenchyma. The risk of recurrence is real if this
rule is not respected.
Finally, we have a major problem when the article
states ‘‘There is no substitute for operative exploration to
make an ultimate determination of resectability.’’ The
authors do not explain how to perform this surgical explo-
ration. In our opinion, the identification of cases where
extended resection is possible should not be based on sur-
gical exploration alone, but also rely on preoperative
imaging confirmed by intraoperative ultrasonography.
In our international experience, we have seen cases
where surgeons attempted extended liver resection, start-
ing to cut through the parenchyma to end in a cul-de-sac,
with the child running into major bleeding-related liver
failure. Despite the good results achieved, we think that
the authors’ message might be misleading and result in
undesired risks for patients.
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Reply to Letters Regarding
Successful Nontransplant
Resection of POST-TEXT III and
IV Hepatoblastoma
We appreciate the insightful replies from the Children’s
Oncology Group (COG; Meyers et al) and Interna-
tional Childhood Liver Tumors Strategy Group (SIO-
PEL; Czauderna et al) regarding our article, ‘‘Successful
nontransplant resection of POST-TEXT III and IV
hepatoblastoma.’’1 We strongly agree with COG and
SIOPEL on: 1) the importance of the PRETreatment
EXTent of Disease (PRETEXT) staging system as an
initial triage tool, 2) the need to avoid hazardous
attempts at resection at centers that lack experience in
advanced pediatric hepatobiliary surgery, and 3) the
clear benefit of transplantation for tumors that remain
truly unresectable after neoadjuvant chemotherapy.2
These points are made emphatically in our article. Our
intended goal was not to undermine the importance of
transplantation in the treatment of very large hepato-
blastoma, but to point out that in a substantial propor-
tion of children who might now be steered toward
transplantation, successful nontransplant resection can
be achieved and a decision to perform transplantation
should not always be based on PRETEXT or POST-
TEXT staging alone. The SIOPEL group itself has
demonstrated that 37% of children with hepatoblas-
toma are overstaged by the PRETEXT system when
compared to pathology findings.3
To comment on the specific issues raised in both let-
ters regarding the accuracy of the preoperative staging, all
our patients underwent imaging at Children’s Memorial
Hospital immediately prior to resection, even though
initial imaging from the referral center was lacking in
some patients. Therefore, accurate POST-TEXT staging
was available in all cases.
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Both letters state that separate wedge resections of
widely separate nodules or the shaving of margins off
portal structures are not standard practices and should
not be recommended when liver transplantation is avail-
able. These comments speak to the very point of the ar-
ticle and are best addressed by our results. We would
argue that because these methods result in a high cure
rate without the need for transplantation, they should
be considered for use more frequently under the right
circumstances.
Our determination about which tumors might have
been otherwise considered for transplantation was based
on published SIOPEL guidelines stating that ‘‘If the tu-
mor remained localized to the liver but still remained
unresectable (PRETEXT group IV or III tumors in con-
tact with hepatic vein or portal vein(s) precluding radical
excision, or centrally located hepatoblastoma), liver trans-
plantation was recommended as primary surgery.’’4 We
agree that most PRETEXT III tumors truly invading or
encasing both portal venous branches (P2) require the
patient to undergo transplantation. In our experience, the
distinction between PRETEXT III tumors that invade the
portal bifurcation versus those that abut and compress it
may be impossible to make by imaging alone and requires
surgical dissection of the portal structures to determine
resectability.
Excellent results were achieved with careful separa-
tion of these tumors off the portal or hepatic veins, often
with little or no margin of normal tissue at the resection
margin. We agree with the comments by Meyers et al
regarding the uncertain significance of less-than-ideal
resection margins. We know of no good evidence that
microscopically positive margins along the portal vessels
are associated with adverse oncologic outcome in hepato-
blastoma. We agree that this is an important area for
future research, but in the meantime, we feel that the cur-
rent evidence supports the aggressive position described in
our article, in which resection for cure is possible even
without an ideal margin of normal tissue.
Both letters comment on the lack of detail regarding
the technique for surgical exploration. This was beyond
the scope of the article, but we feel that this is an extension
of the method proposed in the letter by Meyers and col-
leagues of combining preoperative imaging with intra-
operative ultrasound. However, rather than basing the
decision solely on intraoperative ultrasound, we also advo-
cate mobilization of the liver.
We have long advocated for transplantation for
patients who have liver tumors that are truly unresectable.
Eight of the 23 patients in this series underwent transplan-
tation, and several more not included here underwent
transplantation based on the POST-TEXT imaging
alone. Moreover, all families of patients undergoing
exploration for extended resection are prepared for the
possibility of transplantation. However, transplantation is
not without its drawbacks. Until the shortage of organs
can be resolved, and the long-term consequences of
lifelong immune suppression mitigated by tolerance strat-
egies, it is essential to avoid transplantation when an equiva-
lent alternative is possible. On the other hand, because
survival after primary transplant for hepatoblastoma is excel-
lent, and poor after rescue transplant,5 it is incumbent upon
advocates for advanced liver resection to achieve equivalent
results. Our single-institution case series demonstrates that
excellent results are achievable with resection of very large
tumors in experienced hands. We look forward to future
studies on this topic from multi-institutional study groups.
REFERENCES
1. Lautz TB, Ben-Ami T, Tantemsapya N, Gosiengfiao Y,
Superina RA. Successful nontransplant resection of POST-
TEXT III and IV hepatoblastoma. Cancer. 2011;117:1976-
1983.
2. Browne M, Sher D, Grant D, et al. Survival after liver
transplantation for hepatoblastoma: a 2-center experience.
J Pediatr Surg. 2008;43:1973-1981.
3. Aronson DC, Schnater JM, Staalman CR, et al. Predictive
value of the pretreatment extent of disease system in hepato-
blastoma: results from the International Society of Pediatric
Oncology Liver Tumor Study Group SIOPEL-1 study.
J Clin Oncol. 2005;23:1245-1252.
4. Otte JB, de Ville de Goyet J, Reding R. Liver transplanta-
tion for hepatoblastoma: indications and contraindications
in the modern era. Pediatr Transplant. 2005;9:557-565.
5. Otte JB, Pritchard J, Aronson DC, et al; International
Society of Pediatric Oncology (SIOP). Liver transplanta-
tion for hepatoblastoma: results from the International
Society of Pediatric Oncology (SIOP) study SIOPEL-1
and review of the world experience. Pediatr Blood Cancer.
2004;42: 74-83.
Timothy B. Lautz, MD
Riccardo A. Superina, MD
Department of Surgery
Children’s Memorial Hospital
Feinberg School of Medicine of Northwestern University
Chicago, Illinois
DOI: 10.1002/cncr.26710, Published online: July 3, 2012 in
Wiley Online Library (wileyonlinelibrary.com)
Correspondence
Cancer August 15, 2012 4093
